Reuters logo
1 个月内
BRIEF-Adaptimmune announces data from NY-ESO study in Synovial Sarcoma at ASCO annual meeting
2017年6月5日 / 下午2点12分 / 1 个月内

BRIEF-Adaptimmune announces data from NY-ESO study in Synovial Sarcoma at ASCO annual meeting

1 分钟阅读

June 5 (Reuters) - Adaptimmune Therapeutics PLC:

* Adaptimmune announces an oral presentation on data from NY-ESO study in Synovial Sarcoma and four trials in progress posters at the American Society Of Clinical Oncology (ASCO) annual meeting

* From ongoing NY-ESO Synovial Sarcoma study, NY-ESO continues to be generally well-tolerated

* From ongoing NY-ESO Synovial Sarcoma study, initial anti-tumor activity observed in all ongoing cohorts Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below